Illumina, INC 8-K filings

Illumina, Inc. has entered into a new $1 billion senior unsecured five-year revolving credit facility, replacing its existing agreement.

Illumina, Inc. announced an offering of $300 million in 4.950% notes due 2029 to refinance existing debt maturing in September 2026.

Illumina, Inc. has entered into a settlement agreement to dismiss a shareholder lawsuit related to its GRAIL acquisition, with a court hearing scheduled for November 2, 2026.

Illumina announced strong second quarter 2026 financial results, with revenue increasing 9.5% year-over-year and raising its full-year revenue and EPS guidance.

Illumina, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all director nominees were elected and the appointment of Ernst & Young LLP as independent auditor was ratified.

Illumina reported Q1 2026 revenue of $1.09 billion and announced a new $1.5 billion share repurchase program.

Illumina, Inc. announced the upcoming retirement of three directors and the nomination of David P. King to its Board.

Illumina reported a strong finish to fiscal year 2025 with a return to growth, driven by clinical market expansion and strategic acquisitions, and provided optimistic 2026 guidance.

Illumina, Inc. has finalized its acquisition of SomaLogic's proteomics business for $350 million cash, expanding its multiomics capabilities.

Illumina announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, reporting revenue growth in Q4 but flat full-year revenue.

Illumina announced the appointment of Dr. Eric Green as Chief Medical Officer and the departure of Chief Commercial Officer Everett Cunningham.

Illumina, Inc. has successfully completed a public offering of $500 million in 4.750% notes maturing in 2030, intended for general corporate purposes including debt repayment and a proposed acquisition.

Illumina, Inc. announced an underwriting agreement for the issuance and sale of $500 million aggregate principal amount of 4.750% notes due 2030, with proceeds intended for general corporate purposes including debt repayment and the SomaLogic acquisition.

Illumina reported third-quarter 2025 financial results exceeding revenue and earnings guidance, driven by clinical segment acceleration and an improved full-year outlook.

Illumina reported second-quarter 2025 financial results that surpassed its own guidance, driven by strong clinical segment growth and operational efficiency, leading to an upward revision of its full-year financial expectations.

Illumina, Inc. has announced a definitive agreement to acquire SomaLogic's aptamer-based and functional proteomics business from Standard BioTools Inc. for $350 million in cash, with potential additional milestone payments and royalties, aiming to accelerate its multiomics strategy and expand its presence in the proteomics market.

Illumina, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the election of eleven directors, ratification of Ernst & Young LLP as auditors, advisory approval of executive compensation, and the Second Amended and Restated 2015 Stock and Incentive Plan.

Illumina's Q1 2025 core revenue dipped slightly, and the company has revised its full-year outlook downward due to evolving policy and geopolitical factors.

Illumina appoints Scott Gottlieb as Board Chair and welcomes Keith Meister as a new director, while Stephen MacMillan retires.

Carissa Rollins, Chief Information Officer of Illumina, Inc., will retire effective April 11, 2025.

Illumina addresses recent developments in China, including export restrictions, and announces a cost reduction program and fiscal year 2025 non-GAAP diluted EPS guidance of approximately $4.50.

Illumina announces its Q4 and fiscal year 2024 financial results, with core Illumina revenue up 1% in Q4 and provides guidance for fiscal year 2025.

Illumina has disclosed additional impairment charges of $14 million related to a further reduction in its real estate footprint, specifically a property in San Diego, California.

Illumina reports preliminary unaudited financial results for Q4 and fiscal year 2024, and provides a preliminary outlook for fiscal year 2025, ahead of its presentation at the J.P. Morgan Healthcare Conference.

Illumina's Q3 2024 results show a slight revenue decrease year-over-year, but improved operating margins, leading to a revised full-year outlook.

Illumina's General Counsel, Charles Dadswell, will transition out of his role, moving into an advisory position until March 31, 2025, with Scott Davies appointed as Interim General Counsel.

Illumina has successfully issued $500 million in new notes to repay its outstanding credit agreement, marking a significant financial maneuver.

Illumina has priced a $500 million debt offering to help repay debt incurred from the GRAIL spin-off.

Illumina's second quarter results show a revenue decline year-over-year, but the company has raised its non-GAAP operating margin guidance and completed the spin-off of GRAIL.

Illumina estimates a total of $1.886 billion in impairment charges for goodwill and IPR&D related to GRAIL in the second quarter of 2024, stemming from the planned spin-off.